Intellia Therapeutics, Inc.
US ˙ NasdaqGM ˙ US45826J1051

SecurityNTLA / Intellia Therapeutics, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership511,240 shares
Latest Disclosed Value $ 4,596,048
Barclays Plc ownership in NTLA / Intellia Therapeutics, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 511,240 shares of Intellia Therapeutics, Inc. (US:NTLA) valued at $4,596,048 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 488,226 shares of Intellia Therapeutics, Inc.. This represents a change in shares of 4.71% during the quarter. The current value of the position is $6,656,345 USD.

Barclays Plc has a history of taking positions in derivatives of the underlying security (NTLA) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

NTLA / Intellia Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 511,240 23,014 4.71 4,596 -45.49 0.0011
2026-03-31 2025-09-30 13F/A-3 INTELLIA THERAPEUTICS COM 45826J105 488,226 -29,921 -5.77 8,432 73.48 0.0018
2026-03-19 2025-09-30 13F/A-2 INTELLIA THERAPEUTICS COM 45826J105 292,795 -225,352 6,017 0.0016
2025-11-12 2025-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 488,226 -29,921 8,432 0.0018
2026-02-27 2025-06-30 13F/A-2 INTELLIA THERAPEUTICS COM 45826J105 518,147 278,051 115.81 4,860 184.71 0.0011
2025-08-14 2025-06-30 13F/A-1 INTELLIA THERAPEUTICS COM 45826J105 518,147 278,051 5 0.0011
2025-08-13 2025-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 518,147 278,051 5 0.0004
2026-03-17 2025-03-31 13F/A-1 INTELLIA THERAPEUTICS COM 45826J105 240,096 -71,536 -22.96 1,707 -53.01 0.0005
2025-05-15 2025-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 240,096 -71,536 2 0.0005
2026-03-19 2024-12-31 13F/A-1 INTELLIA THERAPEUTICS COM 45826J105 311,632 18,837 6.43 3,634 -39.61 0.0010
2025-02-13 2024-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 311,632 18,837 4 0.0010
2026-03-31 2024-09-30 13F/A-2 INTELLIA THERAPEUTICS COM 45826J105 292,795 89,422 43.97 6,017 32.19 0.0016
2024-11-19 2024-09-30 13F/A-1 INTELLIA THERAPEUTICS COM 45826J105 292,795 89,422 6 0.0016
2024-11-15 2024-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 292,795 89,422 6 0.0016
2026-03-23 2024-06-30 13F/A-1 INTELLIA THERAPEUTICS COM 45826J105 203,373 18,078 9.76 4,551 -10.71 0.0014
2024-08-14 2024-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 203,373 18,078 5 0.0014
2026-03-24 2024-03-31 13F/A-1 INTELLIA THERAPEUTICS COM 45826J105 185,295 -166,035 -47.26 5,097 -52.42 0.0018
2024-05-15 2024-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 185,295 -166,035 5 0.0018
2026-03-25 2023-12-31 13F/A-1 INTELLIA THERAPEUTICS COM 45826J105 351,330 94,704 36.90 10,712 32.02 0.0039
2024-02-15 2023-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 351,330 94,704 11 0.0039
2026-03-26 2023-09-30 13F/A-1 INTELLIA THERAPEUTICS COM 45826J105 256,626 33,558 15.04 8,115 -10.80 0.0051
2023-11-07 2023-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 256,626 33,558 8 0.0051
2026-03-30 2023-06-30 13F/A-2 INTELLIA THERAPEUTICS COM 45826J105 223,068 -2,585 -1.15 9,097 8.16 0.0058
2023-09-20 2023-06-30 13F/A-1 INTELLIA THERAPEUTICS COM 45826J105 223,068 -2,585 9 0.0058
2023-08-03 2023-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 223,068 -2,585 9 0.0057
2026-03-30 2023-03-31 13F/A-1 INTELLIA THERAPEUTICS COM 45826J105 225,653 -34,214 -13.17 8,410 -7.24 0.0039
2023-05-04 2023-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 225,653 -34,214 8 0.0039
2026-03-30 2022-12-31 13F/A-1 INTELLIA THERAPEUTICS COM 45826J105 259,867 75,296 40.80 9,067 -12.24 0.0041
2023-02-13 2022-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 259,867 75,296 9 0.0041
2022-11-03 2022-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 184,571 77,673 72.66 10,330 86.73 0.0113
2022-08-12 2022-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 106,898 6,061 6.01 5,532 -24.50 0.0034
2022-05-16 2022-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 100,837 -37,922 -27.33 7,327 -55.34 0.0057
2022-02-23 2021-12-31 13F/A-1 INTELLIA THERAPEUTICS COM 45826J105 138,759 62,574 82.13 16,407 60.51 0.0061
2022-02-14 2021-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 138,759 62,574 16,407 0.0019
2021-11-09 2021-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 76,185 35,823 88.75 10,222 56.44 0.0046
2021-08-13 2021-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 40,362 -52,505 -56.54 6,534 -12.32 0.0031
2021-05-13 2021-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 92,867 75,801 444.16 7,452 703.02 0.0040
2021-02-11 2020-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 17,066 -12,993 -43.22 928 55.44 0.0005
2020-11-12 2020-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 30,059 22 0.07 597 -5.54 0.0004
2020-08-12 2020-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 30,037 3,874 14.81 632 97.50 0.0005
2020-05-13 2020-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 26,163 -19,364 -42.53 320 -52.10 0.0003
2020-02-10 2019-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 45,527 25,989 133.02 668 156.92 0.0004
2019-11-15 2019-09-30 13F/A-1 INTELLIA THERAPEUTICS COM 45826J105 19,538 -5,706 -22.60 260 -37.05 0.0002
2019-11-14 2019-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 19,538 -5,706 260 60.1123
2019-08-14 2019-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 25,244 15,725 165.20 413 154.94 0.0003
2019-05-15 2019-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 9,519 -5,768 -37.73 162 -22.49 0.0001
2019-02-14 2018-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 15,287 -1,018 -6.24 209 -55.15 0.0002
2018-11-14 2018-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 16,305 8,839 118.39 466 127.32 0.0003
2018-08-14 2018-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 7,466 -12,312 -62.25 205 -50.72 0.0002
2018-05-15 2018-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 19,778 10,483 112.78 416 132.40 0.0003
2018-02-14 2017-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 9,295 2,367 34.17 179 4.07 0.0001
2017-11-14 2017-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 6,928 4,849 233.24 172 421.21 0.0002
2017-08-14 2017-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 2,079 -16,793 -88.98 33 -87.64 0.0000
2017-05-15 2017-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 18,872 7,659 68.30 267 80.41 0.0003
2017-02-14 2016-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 11,213 11,145 16,389.71 148 14,700.00 0.0002
2016-11-14 2016-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 68 -422 -86.12 1 -90.00 0.0000
2016-08-12 2016-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 490 490 10 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-11-19 2024-09-30 13F/A INTELLIA THERAPEUTICS OPT Call 0 0 n/a n/a n/a
2026-03-31 2024-09-30 13F/A INTELLIA THERAPEUTICS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-11-15 2024-09-30 13F INTELLIA THERAPEUTICS OPT Call 0 0 n/a n/a n/a
2026-03-23 2024-06-30 13F/A INTELLIA THERAPEUTICS OPT Call 45,400 -39.06 1,016 -50.41 n/a n/a n/a
2024-08-14 2024-06-30 13F INTELLIA THERAPEUTICS OPT Call 45,400 1 n/a n/a n/a
2026-03-24 2024-03-31 13F/A INTELLIA THERAPEUTICS OPT Call 74,500 73.26 2,049 56.29 n/a n/a n/a
2024-05-15 2024-03-31 13F INTELLIA THERAPEUTICS OPT Call 74,500 2 n/a n/a n/a
2026-03-25 2023-12-31 13F/A INTELLIA THERAPEUTICS OPT Call 43,000 1,311 n/a n/a n/a
2024-02-15 2023-12-31 13F INTELLIA THERAPEUTICS OPT Call 43,000 1 n/a n/a n/a
2022-05-16 2022-03-31 13F INTELLIA THERAPEUTICS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2022-02-23 2021-12-31 13F/A INTELLIA THERAPEUTICS OPT Call 6,700 -87.29 793 -88.78 n/a n/a n/a
2022-02-14 2021-12-31 13F INTELLIA THERAPEUTICS OPT Call 6,700 793 n/a n/a n/a
2021-11-09 2021-09-30 13F INTELLIA THERAPEUTICS OPT Call 52,700 -52.99 7,070 -61.05 n/a n/a n/a
2021-08-13 2021-06-30 13F INTELLIA THERAPEUTICS OPT Call 112,100 2.75 18,150 107.29 n/a n/a n/a
2021-05-13 2021-03-31 13F INTELLIA THERAPEUTICS OPT Call 109,100 8,756 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-03-23 2024-06-30 13F/A INTELLIA THERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F INTELLIA THERAPEUTICS OPT Put 0 0 n/a n/a n/a
2026-03-24 2024-03-31 13F/A INTELLIA THERAPEUTICS OPT Put 43,000 -40.44 1,183 -46.30 n/a n/a n/a
2024-05-15 2024-03-31 13F INTELLIA THERAPEUTICS OPT Put 43,000 1 n/a n/a n/a
2026-03-25 2023-12-31 13F/A INTELLIA THERAPEUTICS OPT Put 72,200 2,201 n/a n/a n/a
2024-02-15 2023-12-31 13F INTELLIA THERAPEUTICS OPT Put 72,200 2 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.